| 摘要 |
This invention relates to a novel use of IL-1&bgr;-ligand/IL-1 receptor disrupting compounds (herein referred to as IL-1beta Compounds); such as small molecular compounds disrupting IL-1&bgr; ligand-IL-1 receptor interaction, IL-1&bgr; antibodies or IL-1 receptor antibodies, e.g. IL-1&bgr; binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1&bgr; binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1&bgr; ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
|
